Sofinnova Partners Portfolio Company Amolyt Pharma to be Acquired by AstraZeneca

Contributed by: Business Wire

Logo

Tags

Professional Services

Health

Other Health

Finance

Clinical Trials

Pharmaceutical

Biotechnology

Amolyt Pharma

More Like This

Sofinnova Partners Raises €1.2 Billion to Fuel the Next Wave of Life Sciences Innovation

Sofinnova Partners Exceeds Target With €165M Biotech Acceleration Fund, Europe’s Largest, With Strong Pharma Support

Sofinnova Partners Announces Myricx Bio Agrees to Be Acquired by Novartis

AstraZeneca sets ambition to deliver $80 billion Total Revenue by 2030 and sustained growth post 2030

Sofinnova Partners Closes €650M ($750M) Capital XI, Greatly Exceeding Initial Target to Back Early-Stage Healthcare Deals

Edward Kliphuis, Partner, Sofinnova Digital Medicine Strategy and Simon Turner, Partner, Sofinnova Digital Medicine Strategy (Photo: Sofinnova Partners)

Sofinnova Partners Raises $200M Digital Medicine Fund

Sofinnova Partners Closes Oversubscribed €82 Million Sofinnova MD Start IV Fund to Create the Next Generation of Medtech Companies

Orphalan announces acquisition of Orphelia Pharma